Alnylam Pharmaceuticals, Inc. (ALNY)
312.17
+1.07
(+0.34%)
USD |
NASDAQ |
Mar 20, 16:00
312.29
+0.12
(+0.04%)
After-Hours: 20:00
Alnylam Pharmaceuticals Research and Development Expense (Quarterly) : 372.22M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Pfizer Inc. | 3.133B |
| Eli Lilly & Co. | 3.802B |
| Regeneron Pharmaceuticals, Inc. | 1.481B |
| Bristol Myers Squibb Co. | 2.561B |
| Insmed, Inc. | 254.91M |